Open an account

Anthera Pharmaceuticals

ANTH · OTC

$0.0001+$0.0001 (+0.00%)TodayMarket closed ·
No price history for this range.

About ANTH

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Employees
21
Headquarters
Hayward, California
Listed
Mar 2, 2010
Sector
Health Care
Industry
Biotechnology
Website
anthera.com

ANTH key statistics

Market cap
3.53K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
405
Volume
149
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.001
52 Week low
$0.00

Anthera Pharmaceuticals (ANTH) at a glance

Anthera Pharmaceuticals (ANTH) last traded at $0.0001, with a market cap of 3.53K and a price-to-earnings ratio of 0.00.

Volume so far is 149 shares, below the average of 405 shares a day.

Over the past year Anthera Pharmaceuticals has ranged from $0.00 to $0.001, and now sits 10% of the way up that range.

Anthera Pharmaceuticals met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q1 FY18 it reported -$0.57 per share against an estimate of -$0.561.

ANTH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 21.2% on average.

  1. Q2 FY16: reported -$2.80 per share against an estimate of -$2.50
  2. Q3 FY16: reported -$4.88 per share against an estimate of -$3.06
  3. Q4 FY16: reported -$3.20 per share against an estimate of -$3.31
  4. Q1 FY17: reported -$1.57 per share against an estimate of -$1.41
  5. Q2 FY17: reported -$0.86 per share against an estimate of -$1.11
  6. Q3 FY17: reported -$0.58 per share against an estimate of -$0.9313
  7. Q4 FY17: reported -$0.73 per share against an estimate of -$0.675
  8. Q1 FY18: reported -$0.57 per share against an estimate of -$0.561

Similar companies

Companies in the same industry as Anthera Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.